TY  - EJOU
AU  - QIAN, SITONG 
AU  - FANG, YING 
AU  - YAO, CHENGYUN 
AU  - WANG, YONGSHENG 
AU  - ZHANG, ZHI 
AU  - WANG, XIAOHUA 
AU  - GAO, JIN 
AU  - FENG, YONG 
AU  - SUN, LEI 
AU  - ZOU, RUNYUE 
AU  - ZHOU, GUOREN 
AU  - YE, JINJUN 
AU  - XIA, RUIXUE 
AU  - XIA, HONGPING 

TI  - The synergistic effects of PRDX5 and Nrf2 on lung cancer progression and drug resistance under oxidative stress in the zebrafish models
T2  - Oncology Research

PY  - 2022
VL  - 30
IS  - 2
SN  - 1555-3906

AB  - Previous studies have shown that PRDX5 and Nrf2 are antioxidant proteins related to abnormal reactive oxidative species (ROS). PRDX5 and Nrf2 play a critical role in the progression of inflammations and tumors. The combination of PRDX5 and Nrf2 was examined by Co-immunoprecipitation, western blotting and Immunohistochemistry. H<sub>2</sub>O<sub>2</sub> was applied to affect the production of ROS and induced multi-resistant protein 1 (MRP1) expression in NSCLC cells. The zebrafish models mainly investigated the synergistic effects of PRDX5 and Nrf2 on lung cancer drug resistance under oxidative stress. We showed that PRDX5 and Nrf2 form a complex and significantly increase the NSCLC tissues compared to adjacent tissues. The oxidative stress improved the combination of PRDX5 and Nrf2. We demonstrated that the synergy between PRDX5 and Nrf2 is positively related to the proliferation and drug resistance of NSCLC cells in the zebrafish models. In conclusion, our data indicated that PRDX5 could bind to Nrf2 and has a synergistic effect with Nrf2. Meanwhile, in the zebrafish models, PRDX5 and Nrf2 have significant regulatory impacts on lung cancer progression and drug resistance activities under oxidative stress.
KW  - PRDX5; Nrf2; Oxidative stress; Lung cancer; Drug resistance; Zebrafish models

DO  - 10.32604/or.2022.026302